OncoMed Pharmaceuticals Inc Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2017-09-12: Study NCT03295942; Company role Lead sponsor; Phase Phase 1; Status Terminated.
- 2017-05-02: Study NCT03119428; Company role Lead sponsor; Phase Phase 1; Status Terminated.
- 2017-01: Study NCT03031691; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2016-12: Study NCT03035253; Company role Lead sponsor; Phase Phase 1; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2017-09-12 | NCT03295942 A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors | Lead sponsor | Phase 1 | Terminated | Locally Advanced Malignant Neoplasm; Metastatic Cancer | 24 | 2019-07-04 |
| 2017-05-02 | NCT03119428 A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors | Lead sponsor | Phase 1 | Terminated | Locally Advanced Cancer; Metastatic Cancer | 33 | 2019-05-15 |
| 2017-01 | NCT03031691 A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer | Lead sponsor | Phase 1 | Completed | Metastatic Colorectal Cancer | 7 | 2017-09 |
| 2016-12 | NCT03035253 A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer | Lead sponsor | Phase 1 | Terminated | Metastatic Colorectal Cancer | 16 | 2018-12 |
| 2016-12 | NCT03030287 A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer | Lead sponsor | Phase 1 | Completed | Cancer Ovaries; Cancer Peritoneal; Cancer, Fallopian Tube | 44 | 2020-04 |
| 2016-01 | NCT02722954 A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors | Lead sponsor | Phase 1 | Completed | Locally Advanced or Metastatic Solid Tumors | 29 | 2017-05-19 |
| 2015-07-16 | NCT02482441 A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 | Lead sponsor | Phase 1 | Completed | Advanced Relapsed Tumors; Refractory Solid Tumors | 50 | 2018-03-28 |
| 2015-04-20 | NCT02289898 Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma | Lead sponsor | Phase 2 | Completed Results posted | Pancreatic Cancer | 207 | 2017-09 |
| 2015-02 | NCT02259582 A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer | Lead sponsor | Phase 2 | Completed Results posted | Nonsquamous Nonsmall Cell Neoplasm of Lung | 82 | 2017-04-07 |
| 2014-12-22 | NCT02298387 A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors | Lead sponsor | Phase 1 | Completed | Advanced Solid Tumor Malignancies | 71 | 2017-09-08 |
| 2014-01 | NCT02092363 Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer | Lead sponsor | Phase 1 | Completed | Ovarian Cancer | 37 | 2017-12 |
| 2014-01 | NCT02069145 Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer | Lead sponsor | Phase 1 | Completed | Hepatocellular Cancer; Liver Cancer | 10 | 2017-07 |
| 2013-11 | NCT02050178 Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer | Lead sponsor | Phase 1 | Completed | Pancreatic Cancer; Stage IV Pancreatic Cancer | 26 | 2017-06-15 |
| 2013-09 | NCT02005315 A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer | Lead sponsor | Phase 1 | Completed | Pancreatic Cancer; Stage IV Pancreatic Cancer | 30 | 2017-11 |
| 2013-09 | NCT01973309 A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer | Lead sponsor | Phase 1 | Completed | Metastatic Breast Cancer | 37 | 2017-12 |
| 2013-09 | NCT01957007 A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC | Lead sponsor | Phase 1 | Completed | Solid Tumors | 34 | 2017-06 |
| 2013-08-05 | NCT01952249 A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian | Lead sponsor | Phase 1 | Terminated | Primary Peritoneal Carcinoma | 20 | 2016-07-12 |
| 2013-02 | NCT01778439 A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors | Lead sponsor | Phase 1 | Completed | Relapsed or Refractory Solid Tumors | 48 | 2016-07 |
| 2012-10 | NCT01703572 A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies | Lead sponsor | Phase 1 | Completed | Relapsed or Refractory Lymphoid Malignancies | 24 | 2016-01 |
| 2012-10 | NCT01647828 A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer | Lead sponsor | Phase 1, Phase 2 | Completed Results posted | Stage IV Pancreatic Cancer | 217 | 2016-04 |
| 2012-06 | NCT01608867 A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors | Lead sponsor | Phase 1 | Completed | Solid Tumors | 26 | 2017-06 |
| 2012-01-07 | NCT01859741 A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | Stage IV Small Cell Lung Cancer | 172 | 2017-05-08 |
| 2011-05 | NCT01345201 A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors | Lead sponsor | Phase 1 | Completed | Solid Tumors | 35 | 2014-05 |
| 2010-12 | NCT01277146 A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors | Lead sponsor | Phase 1 | Completed | Solid Tumors | 42 | 2013-05 |
| 2010-09 | NCT01189968 A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer | Lead sponsor | Phase 1 | Completed | Non Small Cell Lung Cancer | 50 | 2016-09 |
| 2010-09 | NCT01189942 A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer | Lead sponsor | Phase 1 | Completed | Colorectal Cancer | 18 | 2011-02 |
| 2010-08 | NCT01189929 A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer | Lead sponsor | Phase 1 | Completed | Pancreatic Cancer | 57 | 2016-12 |
| 2008-08 | NCT00744562 A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors | Lead sponsor | Phase 1 | Completed | Solid Tumors | 42 | 2012-01 |